The use of left bundle branch area pacing (LBBAP) is growing in electrophysiology implanted devices. Two late-breaking studies at Heart Rhythm 2023 highlight the success of LBBAP as an alternative to the standard of care using biventricular pacing.

Results from a pivotal clinical trial presented as a late-breaker at Heart Rhythm 2023 indicate that a new leadless pacemaker technology can deliver cardiac resynchronization therapy in patients who were not able to be treated with conventional CRT and epicardial leads.

The Heart Rhythm Society released a new expert consensus statement on the management of remote device clinics for implantable EP devices.

Heart transplantation centers have significant risks to consider when donors test positive for COVID-19, according to new research published in the Journal of the American College of Cardiology.

Bruce Wilkoff, MD, director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, said the new device could be "an important advancement for heart failure patients."

US Heart and Vascular has been busy in 2023, announcing deals with a new investment firm and multiple cardiology practices in the last two months alone.

Although commercial payors do offer better reimbursement rates, their lack of timeliness in making payments is negatively impacting hospitals.

Malpractice premiums appear to play a significant role in the rankings. Even states with ample job opportunities and low-to-moderate cost of living were ranked poorly due to their high malpractice premiums.

Its use dropped the average time needed to examine a finding at all timepoints from 107 seconds to 65 seconds, with pulmonary nodule assessments benefiting from the greatest reductions.